Pyxis Oncology, Inc. (PYXS) NASDAQ
1.71
-0.07999997(-4.47%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Pyxis Oncology, Inc.
Address
35 Cambridgepark Drive
Boston, MA 02140
United States of America (the)
Phone
617 221 9059
Sector
Healthcare
Industry
Biotechnology
Employees
44
First IPO Date
October 08, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Thomas Civik | Interim CEO & Director | 47,500 | 1969 |
| Jitendra Wadhane | Chief Accounting Officer, Senior Vice President of Finance, Corporate Controller & Principal Financial Officer | 559,050 | 1981 |
| Supriya Roth | Head of Commercial Development | 0 | N/A |
| Donna Regalado | Head of Human Resources | 0 | N/A |
| Balu N. Balasubramanian | Interim Chief Technology Officer | 0 | N/A |
| Charles T. Gombar | Senior Vice President of Portfolio & Program Management | 0 | N/A |
| Chris Cohen | Head of Drug Safety & Pharmacovigilance | 0 | N/A |
| Hongwei Wang | Head of ADC Development & Clinical Strategy | 0 | N/A |
| Jan Pinkas | Chief Scientific Officer | 0 | 1969 |
| Michael Bui | Senior Vice President of Global Regulatory Affairs | 0 | N/A |
| Alex Kane | Senior Vice President of Investor Relations & Capital Markets | 0 | N/A |
| Stephen T. Worsley | Senior Vice President & Chief Business Officer | 0 | 1964 |
| Marsha Crochiere | Head of Translational Medicine & Research | 0 | N/A |
| Shui He | Head of Biometrics | 0 | N/A |
Description
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
